Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review

About this episode

Dr Hanny Al-Samkari discusses recent developments in the treatment of immune thrombocytopenia from the ASH 2025 Annual Meeting.

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia. CME information and select publications here .

People in this episode

Host: Dr. Neil Love

Guest: Dr Hanny Al-Samkari

Topics covered

• immune thrombocytopenia
• Bruton tyrosine kinase inhibitors
• BAFF-R antagonists
• ASH 2025
• hematologic oncology

Keywords

• immune thrombocytopenia
• Bruton tyrosine kinase inhibitors
• BAFF-R antagonists
• ASH 2025
• hematologic oncology
• CME information
• treatment developments

Mentioned in this episode

Organizations: Massachusetts General Hospital

Products: Bruton tyrosine kinase inhibitors, BAFF-R antagonists

More episodes of Hematologic Oncology Update

• Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances · May 23, 2026 · 59 min
• Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances · April 20, 2026 · 59 min
• CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson · April 10, 2026 · 25 min
• Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review · April 1, 2026 · 25 min
• CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson · March 23, 2026 · 24 min
• CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah · March 13, 2026 · 1h 3m